Your search returned 8 results.

Results
	1.	Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. MedStar authors: Hui, Adrian C PMID: 24797495 Year: 2014 Citation: Can. j. diabetes. 38(4):269-72, 2014 Aug. Canadian Journal of Diabetes. 38(4):269-72, 2014 Aug. Institution: MedStar Union Memorial Hospital Medline publication type: Journal Article Form of publication: Journal Article All authors: Hui AC, Lull ME, Lyons-Patterson J, Traina AN, Zahorian TM DOI: http://dx.doi.org/10.1016/j.jcjd.2013.10.006 Add to cart (remove)
	2.	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. [Review] MedStar authors: Aroda, Vanita R PMID: 29364586 Year: 2018 Citation: Diabetes, Obesity & Metabolism. 20 Suppl 1:22-33, 2018 02. Institution: MedStar Health Research Institute Medline publication type: Journal Article Review Form of publication: Journal Article All authors: Aroda VR DOI: https://dx.doi.org/10.1111/dom.13162 Add to cart (remove)
	3.	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors: Aroda, Vanita R PMID: 29397376 Year: 2018 Citation: The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A DOI: https://dx.doi.org/10.1016/S2213-8587(18)30024-X Add to cart (remove)
	4.	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors: Aroda, Vanita R PMID: 27284114 Year: 2016 Citation: Diabetes Care. 39(9):1579-86, 2016 Sep Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T DOI: https://dx.doi.org/10.2337/dc16-0046 Add to cart (remove)
	5.	Safety of eptifibatide when added to bivalirudin during ST-segment elevation myocardial infarction. MedStar authors: Baker, Nevin C Escarcega, Ricardo O Lipinski, Michael J Magalhaes, Marco A Torguson, Rebecca Waksman, Ron PMID: 25178667 Year: 2014 Citation: Cardiovascular Revascularization Medicine. 15(5):278-83, 2014 Jul-Aug. Institution: MedStar Heart & Vascular Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Baker NC, Escarcega RO, Lipinski MJ, Magalhaes MA, Torguson R, Waksman R DOI: http://dx.doi.org/10.1016/j.carrev.2014.06.001 Add to cart (remove)
	6.	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. MedStar authors: Aroda, Vanita R PMID: 31359368 Year: 2019 Citation: Advances in Therapy. 36(9):2310-2326, 2019 09. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Bailey TS, Blonde L, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M DOI: https://dx.doi.org/10.1007/s12325-019-01033-1 Add to cart (remove)
	7.	Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors: Ratner, Robert E PMID: 24650952 Year: 2014 Citation: Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun. Institution: MedStar Health Research Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T DOI: http://dx.doi.org/10.1016/j.jdiacomp.2014.01.012 Add to cart (remove)
	8.	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors: Aroda, Vanita R PMID: 27650977 Year: 2016 Citation: Diabetes Care. 39(11):1972-1980, 2016 Nov Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C DOI: https://dx.doi.org/10.2337/dc16-1495 Add to cart (remove)

Powered by Koha